• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the Risks.

作者信息

Epstein Murray, Pecoits-Filho Roberto, Clase Catherine M, Sood Manish M, Kovesdy Csaba P

机构信息

Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, Florida.

Arbor Research Collaborative for Health, Ann Arbor, Michigan.

出版信息

Clin J Am Soc Nephrol. 2022 Mar;17(3):455-457. doi: 10.2215/CJN.13541021. Epub 2021 Dec 1.

DOI:10.2215/CJN.13541021
PMID:34853060
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8975031/
Abstract
摘要

相似文献

1
Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the Risks.慢性肾脏病患者使用盐皮质激素受体拮抗剂时的高钾血症：认识并降低风险
Clin J Am Soc Nephrol. 2022 Mar;17(3):455-457. doi: 10.2215/CJN.13541021. Epub 2021 Dec 1.
2
Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.除血管紧张素转换酶抑制剂或血管紧张素II受体阻滞剂治疗外，盐皮质激素受体阻断：糖尿病肾病中的一种新兴模式：一项系统评价
Eur J Intern Med. 2014 Feb;25(2):173-6. doi: 10.1016/j.ejim.2013.11.007. Epub 2013 Dec 4.
3
Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.根据是否存在慢性肾脏病，使用醛固酮拮抗剂控制高血压后高钾血症风险的预测因素
Nephron Clin Pract. 2014;128(3-4):381-6. doi: 10.1159/000369138. Epub 2015 Jan 6.
4
Mineralcorticoid receptor blockers in chronic kidney disease.慢性肾脏病中的盐皮质激素受体阻滞剂。
Nefrologia (Engl Ed). 2021 May-Jun;41(3):258-275. doi: 10.1016/j.nefroe.2021.08.001. Epub 2021 Sep 1.
5
Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.聚磺苯乙烯钠可否使氯沙坦和螺内酯强化肾素-血管紧张素-醛固酮系统阻断，从而降低慢性肾脏病、蛋白尿和高钾血症患者的蛋白尿？一项开放标签随机对照试验：MorphCKD。
BMJ Open. 2022 Feb 21;12(2):e057503. doi: 10.1136/bmjopen-2021-057503.
6
Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.醛固酮受体拮抗剂在合并和不合并慢性肾脏病的心力衰竭患者中的肾脏结局。
Cardiorenal Med. 2020;10(1):32-41. doi: 10.1159/000503223. Epub 2019 Oct 30.
7
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.醛固酮阻断治疗控制高血压后高钾血症风险的预测因素。
Am J Nephrol. 2009;30(5):418-24. doi: 10.1159/000237742. Epub 2009 Sep 9.
8
Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.聚磺苯乙烯钠用于治疗耐药性高血压和慢性肾脏病患者的螺内酯：AMBER 研究的原理和设计。
Am J Nephrol. 2018;48(3):172-180. doi: 10.1159/000492622. Epub 2018 Sep 3.
9
Management of Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor: Strategies to Maintain Chronic Kidney Disease Patients with Type II Diabetes on Therapy.肾素-血管紧张素-醛固酮系统抑制剂相关高钾血症的管理：使 2 型糖尿病慢性肾脏病患者维持在治疗中的策略。
Cardiorenal Med. 2024;14(1):191-201. doi: 10.1159/000538389. Epub 2024 Mar 21.
10
Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.服用螺内酯及血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的成年患者高钾血症的患病率
J Med Assoc Thai. 2013 Aug;96(8):905-10.

引用本文的文献

1
Drug Development in Pediatric Chronic Kidney Disease: A Review of Promising Treatments, Old Challenges, and New Strategies.儿童慢性肾脏病的药物研发：对有前景的治疗方法、旧挑战及新策略的综述
Paediatr Drugs. 2025 May;27(3):283-291. doi: 10.1007/s40272-025-00684-8. Epub 2025 Feb 10.
2
Cardiovascular Efficacy and Safety of Finerenone: A Meta-Analysis of Randomized Controlled Trials.非奈利酮的心血管疗效与安全性：一项随机对照试验的荟萃分析
Clin Cardiol. 2025 Feb;48(2):e70065. doi: 10.1002/clc.70065.
3
Hyperkalemia Incidence in Patients With Non-Dialysis Chronic Kidney Disease: A Large Retrospective Cohort Study From United States Clinical Care.非透析慢性肾脏病患者高钾血症的发生率：一项来自美国临床护理的大型回顾性队列研究
Kidney Med. 2024 Jul 25;6(10):100879. doi: 10.1016/j.xkme.2024.100879. eCollection 2024 Oct.
4
Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study.美国高钾血症和慢性肾脏病退伍军人长期使用帕替罗姆及其预后：一项倾向匹配队列研究。
Kidney Med. 2023 Nov 27;6(1):100757. doi: 10.1016/j.xkme.2023.100757. eCollection 2024 Jan.
5
Obesity-Related Kidney Disease: Current Understanding and Future Perspectives.肥胖相关肾病：当前认识与未来展望
Biomedicines. 2023 Sep 9;11(9):2498. doi: 10.3390/biomedicines11092498.
6
Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure.使用钠锆石环硅酸酯降低心力衰竭患者的血钾水平。
ESC Heart Fail. 2023 Apr;10(2):1066-1076. doi: 10.1002/ehf2.14268. Epub 2022 Dec 23.
7
Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.非奈利酮治疗慢性肾脏病的疗效与安全性：一项随机临床试验的系统评价和荟萃分析
Front Pharmacol. 2022 Feb 7;13:819327. doi: 10.3389/fphar.2022.819327. eCollection 2022.

本文引用的文献

1
The RALES Legacy and Finerenone Use on CKD Patients.RALES研究的遗产及非奈利酮在慢性肾脏病患者中的应用
Clin J Am Soc Nephrol. 2021 Sep;16(9):1432-1434. doi: 10.2215/CJN.02150221. Epub 2021 Aug 6.
2
Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.门诊治疗 RAAS 抑制剂相关高钾血症及 1 年复发风险。
Clin J Am Soc Nephrol. 2021 Mar 8;16(3):365-373. doi: 10.2215/CJN.12990820. Epub 2021 Feb 19.
3
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
4
Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.肾脏疾病中的钾离子稳态和血钾紊乱管理：KDIGO 争议会议的结论。
Kidney Int. 2020 Jan;97(1):42-61. doi: 10.1016/j.kint.2019.09.018. Epub 2019 Oct 10.
5
Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena.高钾血症是实施肾素-血管紧张素-醛固酮抑制治疗的一个限制因素：这一限制因素导致既定治疗指南与现实临床领域之间的差距不断扩大。
Kidney Int Suppl (2011). 2016 Apr;6(1):20-28. doi: 10.1016/j.kisu.2016.01.004. Epub 2016 Mar 14.
6
Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.肾素-血管紧张素-醛固酮系统抑制剂临床指南与使用情况之间治疗差距的评估
Am J Manag Care. 2015 Sep;21(11 Suppl):S212-20.
7
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.新型非甾体盐皮质激素受体拮抗剂 BAY 94-8862 在慢性心力衰竭合并轻度或中度慢性肾脏病患者中的安全性和耐受性：一项随机、双盲试验。
Eur Heart J. 2013 Aug;34(31):2453-63. doi: 10.1093/eurheartj/eht187. Epub 2013 May 27.
8
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.随机螺内酯评估研究发表后的高钾血症发生率。
N Engl J Med. 2004 Aug 5;351(6):543-51. doi: 10.1056/NEJMoa040135.